Amarin Corp Plc (AMRN)

[ziploc_1]

KIWI...QUOTE.."Zip ..regards to China , combos etc ......wont matter IF RESPECT EPA does not confirm clinically significant risk reduction and IF Kaiser follows the CV part of MITIGATE for at least 2 yrs past full enrollment ....which would be Sept 1st 2023 .....and doesn't see the CV event lines separate in a clinically significant manner."

On the basis of JELIS and R-IT success, we can reasonably anticipate success with both RESPECT and MITIGATE.

This also would auger success with a fixed dose combo with statin-Vascepa or, even better, with statin-MND-2119....Look at Amarin as a super charged start up....currently selling at close a buck.